• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
CNBX launches new research for Melanoma Drug Candidate

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Melanoma antitumor targeting medicine. The announcement comes amidst the recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor results on Melanoma cell lines.

Read more →

We use cookies to ensure you get the best experience on this website Privacy Policy